Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China
This study provides descriptive evidence regarding the clinical characteristics and outcomes of patients with T2D and CKD who initiated SGLT2i or GLP-1 RA in China. The results are important for understanding the existing HRU and residual risk of severe clinical outcomes in such patient populations. The findings also provide a solid foundation for future research aimed at examining the clinical outcomes of new therapeutic options for T2D and CKD.
Authors
- Yanyan Chen (ORCID: https://orcid.org/0000-0002-9681-6105)
- Alfredo E. Farjat (ORCID: https://orcid.org/0000-0001-6105-350X)
- Liming Chen (ORCID: https://orcid.org/0000-0001-6171-3432)
- Xiucong Deng (ORCID: https://orcid.org/0000-0002-8128-1988)
- Fangfang Liu (ORCID: https://orcid.org/0009-0001-8596-9827)
- Yuqin Liao
- Zhe Xu
- Nikolaus G Oberprieler
- Huan Wei
Institutions
- IQVIA (United Kingdom) (GB)
- Bayer (China) (CN)
- IQ Solutions (US)
- Tianjin Medical University (CN)
- Bayer (Germany) (DE)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-106126
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- AstraZeneca
- Bayer
- Bayer HealthCare